|
1
|
Kurz DJ and Eberli FR: Medical therapy of
coronary artery disease after percutaneous intervention. Curr Opin
Pharmacol. 13:287–293. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Amsterdam EA, Wenger NK, Brindis RG, Casey
DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF,
Kontos MC, et al: 2014 AHA/ACC Guideline for the Management of
Patients with Non-ST-Elevation Acute Coronary Syndromes: A report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Am Coll Cardiol. 64:e139–e228.
2014.PubMed/NCBI View Article : Google Scholar : Erratum in: J Am
Coll Cardiol 64: 2713-2714, 2014.
|
|
3
|
Wallentin L, Becker RC, Budaj A, Cannon
CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et
al: PLATO Investigators: Ticagrelor versus clopidogrel in patients
with acute coronary syndromes. N Engl J Med. 361:1045–1057.
2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Husted S and van Giezen JJ: Ticagrelor:
The first reversibly binding oral P2Y12 receptor
antagonist. Cardiovasc Ther. 27:259–274. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pisters R, Lane DA, Nieuwlaat R, de Vos
CB, Crijns HJ and Lip GY: A novel user-friendly score (HAS-BLED) to
assess 1-year risk of major bleeding in patients with atrial
fibrillation: The Euro Heart Survey. Chest. 138:1093–1100.
2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sato N, Sekiguchi H, Hirose Y and Yoshida
S: Delayed chest wall hematoma caused by progressive displacement
of rib fractures after blunt trauma. Trauma Case Rep. 4:1–4.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ross AM, Gao R, Coyne KS, Chen J, Yao K,
Yang Y, Qin X, Qiao S and Yao M: TUCC Investigators. A randomized
trial confirming the efficacy of reduced dose recombinant tissue
plasminogen activator in a Chinese myocardial infarction population
and demonstrating superiority to usual dose urokinase: The TUCC
trial. Am Heart J. 142:244–247. 2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bhatt DL, Paré G, Eikelboom JW, Simonsen
KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W,
et al: CHARISMA Investigators: The relationship between
CYP2C19 polymorphisms and ischaemic and bleeding outcomes in
stable outpatients: The CHARISMA genetics study. Eur Heart J.
33:2143–2150. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang TY, Chen AY, Roe MT, Alexander KP,
Newby LK, Smith SC Jr, Bangalore S, Gibler WB, Ohman EM and
Peterson ED: Comparison of baseline characteristics, treatment
patterns, and in-hospital outcomes of Asian versus non-Asian white
Americans with non-ST-segment elevation acute coronary syndromes
from the CRUSADE quality improvement initiative. Am J Cardiol.
100:391–396. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dang MT, Hambleton J and Kayser SR: The
influence of ethnicity on warfarin dosage requirement. Ann
Pharmacother. 39:1008–1012. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kang HJ, Clare RM, Gao R, Held C,
Himmelmann A, James SK, Lim ST, Santoso A, Yu CM, Wallentin L, et
al: PLATO Investigators: Ticagrelor versus clopidogrel in Asian
patients with acute coronary syndrome: A retrospective analysis
from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am
Heart J. 169:899–905.e1. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Feng C and Wang L and Wang L: Spontaneous
hematoma in the setting of dual anti-platelet therapy with
ticagrelor: A case report. Oncol Lett. 12:144–146. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Buniello A, MacArthur JAL, Cerezo M,
Harris LW, Hayhurst J, Malangone C, McMahon A, Morales J, Mountjoy
E, Sollis E, et al: The NHGRI-EBI GWAS Catalog of published
genome-wide association studies, targeted arrays and summary
statistics 2019. Nucleic Acids Res. 47 (D1):D1005–D1012.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Varenhorst C, Eriksson N, Johansson Å,
Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James
SK, Katus HA, et al: PLATO Investigators. Effect of genetic
variations on ticagrelor plasma levels and clinical outcomes. Eur
Heart J. 36:1901–1912. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li M, Hu Y, Li H, Wen Z, Hu X, Zhang D,
Zhang Y, Xiao J, Tang J and Chen X: No effect of SLCO1B1 and
CYP3A4/5 polymorphisms on the pharmacokinetics and
pharmacodynamics of ticagrelor in healthy chinese male subjects.
Biol Pharm Bull. 40:88–96. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Holmberg MT, Tornio A, Paile-Hyvärinen M,
Tarkiainen EK, Neuvonen M, Neuvonen PJ, Backman JT and Niemi M:
CYP3A4*22 impairs the elimination of ticagrelor,
but has no significant effect on the bioactivation of clopidogrel
or prasugrel. Clin Pharmacol Ther. 105:448–457. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Tatarunas V, Kupstyte N, Zaliunas R,
Giedraitiene A and Lesauskaite V: The impact of clinical and
genetic factors on ticagrelor and clopidogrel antiplatelet therapy.
Pharmacogenomics. 18:969–979. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li MP, Tang J, Wen ZP, Zhang YJ, Zhang W,
Zhou HH, Zhang ZL and Chen XP: Influence of P2Y12
polymorphisms on platelet activity but not ex-vivo antiplatelet
effect of ticagrelor in healthy Chinese male subjects. Blood Coagul
Fibrinolysis. 26:874–881. 2015.PubMed/NCBI View Article : Google Scholar
|
